BioSpace News Archive

Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data

With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.

December 19, 2025

·

2 min read

·

Tristan Manalac

Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .

Infectious disease

Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

Insmed pointed to a strong placebo response as the reason for the trial’s failure.

December 19, 2025

·

2 min read

·

Tristan Manalac

Sep 21, 2020 Brisbane / CA / USA - BioMarin headquarters in Silicon Valley; BioMarin Pharmaceutical Inc. is an American biotechnology company

Mergers & acquisitions

BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase

BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.

December 19, 2025

·

2 min read

·

Dan Samorodnitsky

3D illustration Cloud with coins hanging for business and money saving concept, Minimal creative scene 3d render.

Rare diseases

Kyowa Kirin Could Get Windfall From Updated Newborn Screening Recommendations

A report from analysts at Jefferies suggested that new screenings for metachromatic leukodystrophy and Duchenne muscular dystrophy could bump sales of the gene therapy Libmeldy by more than $100 million.

December 19, 2025

·

2 min read

·

Dan Samorodnitsky

Pulsing heart collage illustration, sign of life. Isolated human heart organ with glowing red line surrounding, black and white

Cardiovascular disease

Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?

After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.

December 19, 2025

·

5 min read

·

Dan Samorodnitsky

Press Releases

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 19, 2025

·

3 min read

Press Releases

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery